TENX
Tenax Therapeutics, Inc.Company with tickers: TENX
CIK
34956
CUSIP
88032L605
Shares Outstanding
26,525,159
13F Activity (30d)
80 filings
78 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $16,573,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $11,539,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-16,573,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-15,716,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.35 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.35 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |